NCT04129398View on ClinicalTrials.gov

MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)

PHASE3CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

December 27, 2019

Primary Completion Date

October 6, 2022

Study Completion Date

October 6, 2022

Conditions
Cytomegalovirus InfectionCytomegalovirus Disease
Interventions
DRUG

Letermovir tablet

A single 240 mg tablet or two 240 mg tablets letermovir administered orally, once daily for 28 weeks

DRUG

Letermovir IV

IV solution of 240 mg (one vial) or 480 mg (2 vials) letermovir in 250 mL infused over 60 minutes, once daily for 28 weeks

Trial Locations (4)

466-8650

Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital ( Site 0002), Nagoya

060-8604

Sapporo City General Hospital ( Site 0004), Sapporo

565-0871

Osaka University Hospital ( Site 0003), Suita

162-8666

Tokyo Women's Medical University Hospital ( Site 0001), Tokyo

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT04129398 - MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042) | Biotech Hunter | Biotech Hunter